Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck & C : mpany Enters COVID-19 Licensing Deals With Five Indian Manufacturers

04/27/2021 | 07:42am EDT


ę MT Newswires 2021
All news about MERCK & CO., INC.
06/14MERCK & CO., INC. : Ex-dividend day for
FA
06/09MERCKá : to Supply COVID-19 Drug Molnupiravir to US for $1.2 Billion
MT
06/09US Stocks Decline as Investors Await Crucial Inflation Data
MT
06/09Campbell Soup, Comtech fall; Merck, Vertex rise
AQ
06/09Stocks Mixed in Tight Ranges Midday, Bond Yields Fall Ahead of Inflation Data
MT
06/09MIDDAY REPORT : Wall Street Mixed in Tight Ranges Midday, Bond Yields Fall Ahead..
MT
06/09MERCKá : JPMorgan Adjusts Merck's Price Target to $100 From $105, Maintains Over..
MT
06/09MERCKá : in $1.2 Million Agreement to Supply US Government With COVID-19 Antivir..
MT
06/09MERCKá : Announces Supply Agreement with U.S. Government for Molnupiravir, an In..
BU
06/09Merck to Supply U.S. With Oral Covid-19 Treatment
DJ
More news
Financials (USD)
Sales 2021 48 173 M - -
Net income 2021 13 706 M - -
Net Debt 2021 11 622 M - -
P/E ratio 2021 14,5x
Yield 2021 3,44%
Capitalization 193 B 193 B -
EV / Sales 2021 4,25x
EV / Sales 2022 3,97x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 95,45 $
Last Close Price 75,45 $
Spread / Highest target 39,2%
Spread / Average Target 26,5%
Spread / Lowest Target -0,60%
EPS Revisions
Managers and Directors
NameTitle
Kenneth C. Frazier Chairman & Chief Executive Officer
Robert M. Davis President
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-7.76%193 120
JOHNSON & JOHNSON5.08%434 405
ROCHE HOLDING AG10.68%328 612
PFIZER, INC.7.66%224 747
NOVARTIS AG-0.39%208 035
ABBVIE INC.7.70%203 857